Why the study?
Doxorubicin clinical use is limited by complex cardiotoxicity, prompting growing interest in the protective role and mechanisms of exosomes.
Exosomes show potential as diagnostic biomarkers and therapeutic agents for mitigating doxorubicin-induced cardiotoxicity.
Answers are grounded in this paper and cite their sources.
Exosomes may offer DIC targets; leaves open clinical translation from mechanistic insights.
Doxorubicin (DOX) is a class of effective chemotherapeutic agents widely used in clinical practice. However, its use has been limited by cardiotoxicity. The mechanism of DOX‐induced cardiotoxicity (DIC) is complex, involving oxidative stress, Ca 2+ overload, inflammation, pyroptosis, ferroptosis, apoptosis, senescence, etc. Exosomes (EXOs), as extracellular vesicles (EVs), play an important role in the material exchange and signal transmission between cells by carrying components such as proteins and RNAs. More recently, there has been a growing number of publications focusing on the protective effect of EXOs on DIC. Here, this review summarized the main mechanisms of DIC, discussed the mechanism of EXOs in the treatment of DIC, and further explored the value of EXOs as diagnostic biomarkers and therapeutic strategies for DIC.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: